GILD vs MRNA
Gilead Sciences (GILD) and Moderna (MRNA) compared side by side. Gilead Sciences (GILD) is larger, with a market cap of $193.5B versus $79.9B for Moderna, about 2.4 times the size. MRNA returned +662.3% over the past year including dividends, versus +32.4% for GILD, through October 23, 2026..
Head to head
| Metric | GILD | MRNA |
|---|---|---|
| Market cap | $193.5B | $79.9B |
| P/E (TTM) | — | — |
| Forward P/E | 15.6x | -43.6x |
| Revenue (TTM) | $30.5B | $2.2B |
| Revenue growth | 10.2% | 2.1% |
| Gross margin | 79.6% | -66.0% |
| Operating margin | 33.7% | -557.9% |
| Free cash flow | $12.9B | -$1.2B |
| Dividend yield | 2.10% | None |
| 1-year return | +32.4% | +662.3% |
| 5-year return (annual) | +22.6% | -9.3% |
| Max drawdown | -71% | -95% |
| FI Handbook grade | B- | F |
Highlighted: the stronger figure on metrics where higher or lower is clearly better.
Growth of $10,000 (5 years, price only)
$0
$10.0K
$20.0K
20222023202420252026
GILD vs MRNA FAQ
Which is bigger, GILD or MRNA?
Gilead Sciences (GILD) is larger, with a market cap of $193.5B versus $79.9B for Moderna, about 2.4 times the size.
Which stock performed better over the past year, GILD or MRNA?
MRNA returned +662.3% over the past year including dividends, versus +32.4% for GILD, through October 23, 2026.
Which pays a higher dividend, GILD or MRNA?
GILD yields 2.10%; MRNA does not pay a dividend.
Full pages: Gilead Sciences · Moderna